• Call(WhatsApp Us)

    +8615360806100
  • Email Us

    cherry@laeyo.com
  • 广州市花都区花山镇华辉路18号

    微观化妆品创意产业园E栋整栋

Private Label Eye Serum Manufacturing: From Formula Brief to Retail-Ready Product

An eye serum is one of the most claim-sensitive and pack-sensitive items in a private label lineup: the fill weight is small, the use area is delicate, and a single word on the front…

Category: Eye Care Sourcing Guides • Author: laeyo • Published: 2026-10-08 • Views: 135

An eye serum is one of the most claim-sensitive and pack-sensitive items in a private label lineup: the fill weight is small, the use area is delicate, and a single word on the front panel (“firming,” “de-puffing,” “lash”) can change how the product is classified in your target market. This guide walks a brand owner or sourcing manager through the practical sequence — formula brief, claim and naming lock, packaging compatibility, test plan, label fields, and final documentation — so you can brief a manufacturer with enough precision to get a comparable quote and a retail-ready dossier, not just a sample.

Step 1: Write a formula brief a factory can actually quote

Most slow eye serum projects stall in the first two weeks because the brief is a mood, not a specification. Before you compare prices, put the following on one page and send it to every candidate manufacturer. The same brief to three factories is what makes their quotes comparable.

  • Use area and user: eye contour only — state clearly whether the product may migrate toward the lash line or lid, and whether it is intended for sensitive or reactive users.
  • Target market(s): US, EU/GB, or registration markets (for example Egypt, Botswana, Sierra Leone, South Africa), because the label fields, language, and pre-import registration pathway differ by country.
  • Desired claims: list every claim you intend to print, including the product name. Names are claims.
  • Texture and sensory target: lightweight gel-serum, emulsion, or anhydrous; absorption speed; tackiness tolerance; slip for a rollerball versus a dropper.
  • Key actives and target levels: peptides, caffeine, niacinamide, hyaluronic acid, retinol, acids — with the finished-product concentration you want, not just “with retinol.”
  • Free-from constraints: fragrance-free, essential-oil-free, silicone-free, vegan, or preservative restrictions you must respect.
  • pH window and compatibility notes: some actives only behave in a narrow range; state it so the lab does not reformulate around your claim.
  • Packaging direction: dropper, rollerball, airless pump, or tube — with bottle and carton dimensions if already chosen.
  • Fill size and target shelf life / PAO: typical eye serum fills sit around 10–15 mL, which makes dose control and preservative efficacy harder, not easier.
  • Volume and timeline: first run quantity, reorder expectation, and the date you need goods in hand (work backwards from the retail or marketplace launch date).

Step 2: Lock the three decisions that control everything downstream

Decision A — Claim set and product naming

Decide the claim list before formulation. A cosmetic eye serum may reasonably talk about the appearance of puffiness or the look of fine lines if you can support it; claims to treat an eye condition, or to regrow or lengthen lashes, push the product toward a drug or medicinal classification in most markets and require a different pathway entirely.

  • Avoid names that imply a physiological change: “Lash Growth Serum,” “Dark Circle Treatment,” “Eye Repair Therapy” all carry classification risk.
  • Safer naming direction: “Eye Serum,” “Eye Contour Serum,” “Hydrating Eye Gel” — descriptive, defensible, and easier to register.
  • Every efficacy claim needs a support file. Ask what evidence backs it before it goes on artwork.

Decision B — Packaging format and compatibility

The pack is not a cosmetic afterthought; it is a test article. A dropper bulb, rollerball housing, or airless pump that is incompatible with your formula will fail in the field, not in the lab. Lock the pack and the formula together.

Decision C — Regulatory pathway per market

In the US, an eye serum sold as a cosmetic is labeled under general cosmetic labeling requirements: product identity and net quantity on the principal display panel; responsibility party name and address, ingredient declaration, and any required warnings on an information panel. In the EU/GB, expect a responsible person, PAO or best-before date, batch code, and current restriction checks on colorants, preservatives, and fragrance allergens. In several registration markets, import may require prior registration or notification submitted by a local agent, sometimes with final packaging samples and English-language application materials.

Step 3: Eye-area compliance points that get missed

  • Warnings must be specific, not comforting. “Avoid direct contact with eyes; rinse thoroughly with water if contact occurs” does real work. “Gentle, no irritation” is a marketing slogan and cannot substitute for a safety argument.
  • Do not copy colorant and preservative permissions from a body cream. Eye-area use has its own restrictions in most systems; confirm each colorant and preservative against the intended use area, not just against the formula.
  • Retinol and acids need concentration-level checks. INCI order alone proves nothing — verify the finished-product concentration, the use site, and the current restriction and warning conditions in the market where you sell.
  • Fragrance decisions are labeling decisions. “Fragrance,” “Parfum,” and allergen declarations are handled differently across the US, EU, and Canada. If you go fragrance-free, say so consistently on pack, web, and listing copy.
  • Microbiological risk is elevated. Small-volume, multi-use, water-containing eye products with a dropper or rollerball applicator deserve a documented risk assessment and a preservative efficacy study on the final formula in the final pack.

Step 4: Build a test plan that proves the product, not the concept

Test / document What it proves Must be run on Typical lead time
Accelerated + real-time stability Formula and pack hold pH, viscosity, color, and odor over shelf life Final formula in final pack, upright and inverted 4–8 weeks accelerated; real-time runs in parallel
Preservative efficacy (challenge) test Preservation system is adequate for a multi-use eye product Final formula in final pack (ISO 11930 or an approved equivalent method) 4–6 weeks
Packaging compatibility No leakage, swelling, dosage drift, discoloration, or label lift Final components with final fill 2–6 weeks, including transit simulation
Microbiological limits per batch Released goods meet specification Each production batch 5–10 working days
HRIPT / patch test or consumer use study Supports tolerability language you actually intend to print Final formula, final pack 4–8 weeks
Safety assessment / CPSR (EU/GB) Product may lawfully be placed on the market Final formula, pack, and label 2–4 weeks after data is complete

Ask for the test report itself — not a summary email. Check the batch number, formula version, and pack description on the first page against your order.

Step 5: Freeze the label before you print

Artwork is where compliant projects fail late and expensively. Request a label content sheet covering every field, per market, and get written confirmation from the importer or responsible party in that market before plates are made.

  • Principal display panel: product identity and net quantity, with the net quantity accurate to the actual fill.
  • Information panel: responsibility party name and address, full ingredient declaration in the correct nomenclature, required warnings, batch/lot code, and PAO or best-before date.
  • Language: confirm which language(s) the consumer pack must carry — registration dossiers being in English does not automatically mean the retail label may be English-only.
  • Claim-to-evidence map: one line per claim, naming the study or reference that supports it.
  • Print check: verify dieline, color, barcode scannability, and small-type legibility on the actual bottle, not on a PDF at 400%.

Step 6: Realistic timeline, two ways

Fast safe path (compressed, not cut)

  • Weeks 0–1: brief and claim list locked; packaging shortlisted from existing tooling. Evidence: signed brief, packaging spec sheet.
  • Weeks 1–3: lab develops 2–3 prototypes; you select one. Evidence: prototype submission sheet with formula version.
  • Weeks 3–5: stability and compatibility started immediately on the selected formula in the selected pack. Evidence: protocol with start date and batch.
  • Weeks 5–8: label content review in parallel; pilot run booked. Evidence: approved artwork file with version number.
  • Weeks 8–10: pilot batch, micro release, documentation handoff. Evidence: COA, SDS, stability interim report, challenge test report.

Standard path (lower risk)

  • Add 4–6 weeks for real-time stability data before commercial production.
  • Add 4–8 weeks if a safety assessment or pre-import registration is required in your market.
  • Add 2–4 weeks if you are developing new packaging tooling rather than using an existing mould.

What you may compress: prototype rounds, artwork revision cycles, and shipping mode. What you may not compress: preservative efficacy, packaging compatibility, and label review for your market.

Step 7: Common failure modes and how to prevent them

  • Leaking or seizing dropper/rollerball after two weeks. Root cause: elastomer or ball housing incompatible with the formula’s solvent or oil load. Prevention: compatibility test on the exact components. Request: compatibility report naming component supplier and lot.
  • Viscosity drift making the serum undispenseable. Root cause: formula optimized in bulk, never tested in the pack. Prevention: test dosage at start, middle, and end of simulated use. Request: dose-force and dispense-rate data.
  • Label lifting or wrinkling on a small curved bottle. Root cause: adhesive and substrate mismatch on high-curvature, low-surface-energy bottles. Prevention: adhesion test on filled, chilled, and humidified samples. Request: label adhesion test results plus substrate specification.
  • COA does not match the printed INCI. Root cause: formula changed after artwork approval without document control. Prevention: version-locked formula and label. Request: batch record, COA, and artwork approval tied to the same formula version.
  • Micro or challenge data exists only for bulk, not the final pack. Prevention: specify final pack in the test protocol. Request: the full report with pack description.
  • Claim on pack has no support file. Prevention: claim-to-evidence map signed off before print. Request: study summary per claim.
  • Import held at customs. Root cause: registration or notification not completed by a local agent. Prevention: confirm the pathway and lead time at brief stage. Request: registration status letter or agent confirmation.

Step 8: Cost levers versus red lines

Lever What to do Do not cut Evidence to request
Actives level Optimize to the lowest level that still supports the claim Finished-product concentration versus market restriction Formula spec sheet with assay
Packaging Choose existing stock components over new tooling Compatibility testing on final components Compatibility report
Preservation Simplify the preservative system within permitted limits Challenge test on final pack ISO 11930 (or equivalent) report
Testing scope Skip consumer studies if you drop the corresponding claim Stability, micro, and safety assessment Stability protocol and reports
Label complexity Single-language pack for a single market Market-required fields and warnings Approved artwork with version control

Copy-paste RFQ checklist

Send this to each candidate manufacturer; the replies will be directly comparable.

Share: target market(s) and intended retail channel
Share: product name options and full claim list
Share: fill size, pack format, and any chosen components
Confirm: eye-area use and any lash-line proximity
Confirm: fragrance-free / free-from requirements
Confirm: finished-product active levels and pH window
Provide: packaging dimensions and dieline if available
Request: prototype lead time and number of rounds
Request: stability protocol and duration
Request: preservative efficacy test plan and method
Request: packaging compatibility test scope
Request: microbiological release spec per batch
Request: safety assessment or CPSR availability
Request: claim substantiation approach per claim
Request: label content sheet per market
Request: sample COA, SDS, and spec sheet
Confirm: registration or notification support in market
Confirm: pilot run size and booking lead time
Confirm: documentation package at handoff
Lock: formula version and artwork version before print
Approve: artwork with written importer confirmation
Review: first-article inspection before mass production

FAQ

How long does a private label eye serum take from brief to retail-ready?

With existing packaging and a straightforward cosmetic claim set, plan on roughly 8–10 weeks for prototype, stability start, pilot, and documentation. Add 4–6 weeks if you need real-time stability before launch, and 4–8 weeks more if your market requires a safety assessment or pre-import registration.

Can I use my face serum formula for the eye area?

Not without review. Eye-area use changes the restriction checks for colorants, preservatives, and fragrance, and the smaller pack and applicator change the microbiological and compatibility picture. Treat it as a separate formula and a separate test plan.

Do I need a preservative challenge test if the product is “preservative-free”?

You need a documented risk assessment and a defensible preservation strategy either way. Multi-use eye products with water content and a dropper or rollerball applicator are a high-risk category; ask your lab how the product is protected across its shelf life and ask to see the supporting data.

Can I say my eye serum “reduces dark circles”?

Only with support. Appearance-based wording about the look of the eye contour is more defensible than treatment language, and any claim you print should have a named study or reference behind it. Claims to treat a condition, or to change lash growth, generally move the product into a different regulatory category.

Who approves the final artwork?

The brand owns the artwork, but in registration markets the local importer or responsible party should confirm the final label in writing. Keep that confirmation with the batch record.

This guide is informational only and is not legal advice. Confirm label, claim, and registration requirements against the current regulations of each market you sell in.

Next step

Ready to move from brief to sample? Send your target market(s), SKU list and fill sizes, positioning, packaging direction, and launch date — a complete brief typically shortens quoting and reduces prototype rounds. Request a Quote.

Hi, I'm your LAEYO representative, hope you like this blog post.

With more than 20 years of experience in OEM/ODM/Private Label Cosmetics, I'd love to share valuable knowledge related to cosmetics & skincare products from a top-tier Chinese supplier's perspective.

  • Our team will answer your inquiries within 8 hours.
  • Your information will be kept strictly confidential.

Request received

Thanks — we’ve received your request. Our team will follow up shortly. we typically reply within 8 hours (often sooner).